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A crucial event of apoptosis is the activation of caspase proteases. In mammalian cells, including neurons, caspase activation can be triggered by the release of cytochrome c from the mitochondria. 2, 3 Once released, cytochrome c binds to Apaf-1, inducing its oligomerization and subsequent recruitment of the initiator caspase, procaspase-9, to form the apoptosome complex. This complex results in activation of caspase-9, which can then cleave and activate downstream caspases such as caspase-3, which are responsible for cell death. 3 These major components of the apoptotic pathway have been well characterized through the use of cell-free biochemical studies and in intact cells using mitotic cell lines. However, recent evidence suggests that apoptosis is regulated very differently between mitotic and postmitotic cells. For example, in many mitotic cells such as HeLa cells, HEK 293 cells, primary fibroblasts and naïve PC12 cells, the addition of cytochrome c to cytosolic extracts or injection of cytochrome c into the cytosol of these cells induces rapid caspase activation and apoptosis. [4] [5] [6] [7] [8] In contrast, cytochrome c, although necessary, is not sufficient to induce apoptosis in postmitotic cells such as sympathetic neurons, differentiated PC12 cells and cardiomyocytes. 2, 5, 9, 10 Recently, the X-linked inhibitor of apoptosis protein (XIAP) was identified as the critical regulator of caspase activation in these postmitotic cells. 9, 11 XIAP is a member of a family of inhibitor of apoptosis proteins (IAPs) that have been shown to regulate caspases by directly binding to and inhibiting their function. 12 Whereas cytosolic microinjection of cytochrome c is insufficient to induce apoptosis in wild-type neurons and cardiomyocytes, it is capable of doing so in XIAP-deficient neurons and cardiomyocytes. 9, 11 Although sympathetic neurons are resistant to injection of cytochrome c into their cytosol, they are capable of undergoing cytochrome c-dependent apoptosis when induced by insults such as NGF deprivation and DNA damage. [13] [14] [15] Therefore, in order to undergo apoptosis, neurons must activate signaling events that cause cytochrome c release as well as inactivate XIAP. The mechanism by which neurons overcome XIAP's inhibition of caspases to become sensitive to cytochrome c has been termed 'development of competence' and has been examined in the model of NGF deprivation. 2 In NGF deprivation-induced death, the 'development of competence' is dependent neither on Bax function nor on protein synthesis, but occurs by the selective degradation of XIAP. 11 Whether other apoptotic stimuli, most importantly those involved in pathological situations that engage the cytochrome c-mediated apoptosome pathway, use the same or different mechanisms to overcome XIAP remains unknown.
Previous studies have shown that DNA damage can activate the intrinsic apoptotic pathway leading to cytochrome c release and caspase-dependent cell death in many cell types including sympathetic neurons. 13, 16 Although DNAdamaging agents are commonly used as chemotherapeutics in the treatment of many cancers, they can also cause widespread neurotoxicity in patients. 17 DNA damage has also been observed in neurodegenerative diseases. 16, 18 Therefore, understanding how apoptosis is regulated in neurons in response to DNA damage has clinical significance.
The tumor suppressor p53 has been implicated in the regulation of apoptosis in response to DNA damage in mitotic cells as well as neurons. 16, 19, 20 p53 has been shown to regulate cytochrome c release from the mitochondria both directly 21, 22 and through the transcriptional induction of proapoptotic Bcl-2 proteins such as Bax, Puma and Noxa. 20 In this report, we find that p53 has an additional function to regulate apoptosis even after the point of mitochondrial cytochrome c release in neurons.
We find that the mechanisms by which sympathetic neurons overcome XIAP's inhibition of caspases are distinct between NGF deprivation and DNA damage. Specifically, whereas NGF deprivation induces competence to relieve XIAP by targeting it for degradation, XIAP's inhibition of caspases after DNA damage is overcome by a p53-dependent increase in Apaf-1. Thus, in the absence of p53, DNA-damaged neurons are unable to execute apoptosis in response to cytochrome c because they are incapable of relieving XIAP. These results identify an essential postmitochondrial role of p53 in regulating apoptosis in mammalian neurons.
Results
Etoposide induces cytochrome c release and apoptosome-dependent death. Sympathetic neurons undergoing apoptosis mediated by the apoptosome pathway require not only the release of cytochrome c from mitochondria but must also overcome XIAP's strict inhibition of caspases. Although the mechanism by which XIAP is relieved has been previously studied in the model of NGF deprivation-induced neuronal death, 11 here we examined how XIAP is overcome in sympathetic neurons undergoing apoptosis with DNA damage.
First, we established that sympathetic neurons treated with DNA-damaging agents undergo a cytochrome c and apoptosome-mediated cell death. Sympathetic neurons were treated with the topoisomerase II inhibitor etoposide and cell death was assessed at various time points. In response to etoposide, greater than 70% of sympathetic neurons undergo cell death by 48 h. This death was apoptotic as it could be blocked by the pan-caspase inhibitor zVAD-fmk ( Figure 1a Figure S1 ). Furthermore, this etoposide-induced death resulted in the release of cytochrome c (Figure 1b ) and engaged the apoptosome pathway. Unlike wild-type neurons, sympathetic neurons isolated from Apaf-1 deficient mice were resistant to etoposide (Figure 1c) . Likewise, caspase-3 deficient sympathetic neurons have also recently shown to be resistant to etoposide-induced apoptosis. 23 In sympathetic neurons undergoing apoptosis via the cytochrome c-mediated apoptosome pathway, the removal of XIAP's inhibition on caspases is necessary to permit death. Wild-type neurons are resistant, whereas XIAP-deficient neurons rapidly undergo apoptosis following injection of cytochrome c (Figure 1d) . 11 The observation that etoposide engages death via the apoptosome pathway indicates that etoposide signaling must relieve XIAP's inhibition of caspases in order for cells to die. Indeed, etoposide treatment for 24 h (a time point at which cytochrome c release and cell death are minimal) is able to relieve inhibition of caspases as it sensitizes wild-type neurons to cytochrome c (Figure 1d ). These results indicate that etoposide activates a mechanism that makes neurons permissive for cytochrome c-induced apoptosis before the neurons reach the point of cytochrome c release.
Unlike NGF deprivation, etoposide-induced death requires translation to overcome XIAP. In the model of NGF deprivation-induced neuronal death, XIAP is inactivated by its selective degradation (Figure 2a ). We were surprised to find, however, that neurons treated with etoposide underwent apoptosis yet maintained their XIAP levels (Figure 2a and b) . These results indicate that the mechanisms by which NGF deprivation and DNA damage overcome XIAP are distinct.
The development of competence can be directly determined by assessing the sensitivity of neurons to microinjection of cytochrome c. Only after neurons develop competence (overcome XIAP activity) do they become sensitive to cytosolic cytochrome c. Cytochrome c release is dependent on Bax and protein synthesis, whereas in previous studies we have shown that neither Bax nor protein synthesis is required for the development of competence via degradation of XIAP after NGF deprivation. Therefore, NGF-deprived neurons, both Bax deficient and cycloheximide (CHX) treated, are unable to release cytochrome c, yet develop competence and die with microinjected cytochrome c (Figure 2c ). 2 As the 'development of competence' pathway in etoposidetreated neurons appeared distinct and did not involve the degradation of XIAP, we asked whether this pathway was dependent on Bax or protein synthesis. Bax-deficient or wildtype cycloheximide-treated sympathetic neurons were exposed to etoposide for 24 h, followed by microinjection of cytochrome c and assessment of cell survival. Like the NGFdeprived condition, etoposide treatment induced competence in the Bax-deficient neurons (Figure 2d ). However, unlike NGF-deprived neurons, etoposide-treated neurons failed to develop competence in the presence of cycloheximide and remained resistant to cytochrome c (Figure 2d ). These results indicate that the mechanism by which XIAP is overcome to develop competence in etoposide-treated neurons requires protein synthesis.
Apaf-1 is markedly induced in etoposide-treated sympathetic neurons. We have shown previously that Apaf-1 levels and the ability of XIAP to inhibit apoptosis are inversely coupled in cells. 5 Under conditions where Apaf-1 levels are low, such as in postmitotic sympathetic neurons and cardiomyocytes, endogenous XIAP is an effective inhibitor of caspases. 9, 11 In contrast, in mitotic cells where Apaf-1 levels are high, equivalent levels of XIAP are unable to strictly block caspase activation in response to cytosolic cytochrome c.
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Based on this observation, we speculated that an increase in Apaf-1 levels could be a mechanism by which sympathetic neurons disengage XIAP's brake on caspase activation in response to DNA damage. We examined whether Apaf-1 levels are increased in sympathetic neurons treated with etoposide. Indeed, Western blot analysis shows that Apaf-1 protein levels were elevated by 24 h following treatment with etoposide ( Figure 3a) . In contrast, no significant increase in Apaf-1 was seen after NGF deprivation. This increase in Apaf-1 with DNA damage was also seen at the transcriptional level ( Figure 3b ). Similar increases in Apaf-1 have also been reported in cortical neurons following treatment with camptothecin or after traumatic brain injury. 24, 25 These data suggest that Apaf-1 induction could be necessary for disengaging XIAP's brake on caspase activation to permit apoptosis in neurons.
p53-deficient neurons are unable to develop competence in response to DNA damage. In the context of cell death, two functions of p53 have received much attention. First, p53 transcriptionally regulates proapoptotic Bcl-2 family members such as Bax, Puma and Noxa in response to DNA damage, which are important upstream activators of cytochrome c release. [26] [27] [28] Second, a transcriptional-independent role has been described for p53 in which it acts directly at the mitochondria to induce cytochrome c release. 21, 22, 29, 30 Recently, p53 has also been identified as a transcriptional activator of Apaf-1, but the importance of this activity has remained unclear. 24, 31 As the increase in Apaf-1 could be a potential mechanism by which XIAP is relieved to permit neuronal apoptosis, we investigated the specific importance of p53 in this process. First, we examined whether p53 deficiency blocks apoptosis in sympathetic neurons in response to etoposide. While less than 10% of wild-type sympathetic neurons remained viable 60 h after etoposide treatment, greater than 80% of p53-deficient neurons survived at this time ( Figure 4a ). As p53 has been shown to induce Puma, an event that is required for cytochrome c release in response to DNA damage in sympathetic neurons, 14 we anticipated that p53-deficient neurons might be resistant to apoptosis at multiple points in the apoptotic pathway. Consistent with this known premitochondrial function of p53 in neurons, while the majority of wildtype neurons had released cytochrome c by 36 h of etoposide treatment, p53-deficient neurons retained cytochrome c in the mitochondria (Supplementary Figure S2) .
To specifically examine whether p53 is also important downstream of cytochrome c, we investigated whether p53-deficient neurons fail to become sensitive to cytochrome c following DNA damage. Wild-type and p53-deficient Figure S2 ), followed by microinjection with cytochrome c. Activation of the apoptotic pathway directly at the point of cytosolic cytochrome c is necessary as it allows one to bypass the known defect of cytochrome c release found in p53-deficient neurons (Supplementary Figure S2) . Unlike etoposide-treated wild-type neurons, which underwent apoptosis after cytochrome c injections, etoposide-treated, p53-deficient neurons remained resistant to cytochrome c injection unless XIAP was removed by coinjection of Smac protein (Figure 4b ). Injections with rhodamine dextran alone did not induce death in wild-type or p53-deficient etoposide-treated neurons.
To determine whether the inability of p53-deficient neurons to develop competence was specific to DNA damage, we asked whether p53-deficient neurons were able to develop competence in response to NGF deprivation. Wild-type or p53-deficient sympathetic neurons were deprived of NGF in the presence of cycloheximide (to prevent cytochrome c release) for 24 h. Consistent with our expectations, both wildtype and p53-deficient neurons developed competence and were sensitive to microinjection of cytochrome c (Figure 4c ). Thus, p53 is selectively important for the development of competence in response to DNA damage, which involves upregulation of Apaf-1, but not NGF deprivation, which involves the degradation of XIAP.
To confirm that the inability of p53-deficient neurons to undergo apoptosis in response to cytochrome c was due to XIAP's inhibition of caspases, we asked whether p53-deficient neurons became sensitive to cytochrome c following direct inactivation of XIAP. Indeed, injection of cytochrome c along with Smac (an inhibitor of IAPs), but not cytochrome c alone nor Smac alone, induced apoptosis in p53-deficient neurons, indicating that all the necessary apoptosomal components are present and capable of activation in the p53-deficient neurons if XIAP is removed (Supplementary Figure S3) .
Thus, in sympathetic neurons, p53 is required to overcome XIAP (develop competence) to permit cytochrome c-mediated apoptosis following DNA damage.
p53 links Apaf-1 induction with XIAP inactivation during DNA damage-induced apoptosis in neurons. To investigate whether p53 is necessary for the induction of Apaf-1 protein in response to DNA damage, neurons from p53-heterozygous or p53-deficient mice were either left untreated or treated with etoposide. Western analysis revealed that whereas the levels of Apaf-1 protein increased following etoposide treatment in wild-type and p53-heterozygous neurons (Figures 3a and 5a ), Apaf-1 was not induced in p53-deficient neurons under these conditions (Figure 5a ). Thus, etoposide-mediated induction in Apaf-1 in sympathetic neurons was p53-dependent. We also note that p53 deficiency did not affect basal levels of Apaf-1, as Apaf-1 levels were comparable between p53-heterozygous and p53-deficient neurons.
If the resistance of p53-deficient neurons to develop competence is due to the specific inability of these cells to upregulate Apaf-1 in response to etoposide, then restoration of Apaf-1 induction in p53-deficient neurons would be expected to restore the ability of these neurons to develop competence following DNA damage. To test this, p53-deficient sympathetic neurons were injected with plasmid DNA encoding either Apaf-1 or vector alone, along with EGFP to mark injected cells. After 24 h, neurons were treated with etoposide for 24 h, followed by microinjection of cytochrome c. Together, these data show that a p53-mediated induction of Apaf-1 is necessary to overcome XIAP to permit cytochrome c to induce apoptosis in neurons in response to DNA damage.
Discussion
In this study, we have examined how the strict inhibition of caspases by endogenous XIAP is relieved when neurons undergo apoptosis following DNA damage. We find that the mechanisms by which XIAP is overcome in sympathetic neurons undergoing developmental apoptosis by NGF withdrawal and pathological apoptosis by DNA damage are distinct. Whereas NGF deprivation relieves XIAP by its selective degradation, 11 XIAP levels remained unchanged after DNA damage (Figure 2a and b) . In contrast to NGF deprivation, the development of competence after DNA damage required protein synthesis. Consistent with this requirement, we found that Apaf-1 was markedly induced in neurons undergoing apoptosis with DNA damage (Figure 3a) . Our results identify an important function of p53 in the development of competence, as p53-deficient neurons failed to induce Apaf-1 after DNA damage (Figure 5a) . We examined the specific importance of Apaf-1 upregulation in relieving XIAP during DNA damage-induced apoptosis, and found that in the absence of an Apaf-1 induction, p53-deficient neurons failed to develop competence in response to DNA damage (Figure 4b) . Importantly, restoring Apaf-1 induction by overexpression of Apaf-1 in p53-deficient neurons restored their ability to relieve XIAP, permitting cytochrome c to induce apoptosis (Figure 5b) .
These results validate our previous model, which proposed that the effectiveness of endogenous XIAP to inhibit apoptosis is coupled to Apaf-1 activity in cells. Mitotic cells, which express high levels of Apaf-1, readily undergo apoptosis in response to cytochrome c, without the need to eliminate endogenous XIAP. In contrast, sympathetic neurons have low levels of Apaf-1, allowing endogenous XIAP to effectively inhibit cytochrome c-dependent caspase activation. 5 As Apaf-1 is the limiting component of the apoptosome in these neurons, this model predicts that elevating levels of Apaf-1 alone would be sufficient to increase the number of functional apoptosomes and overcome XIAP. In this study, we describe a pathological situation in which the coupling of Apaf-1 and XIAP becomes a critical regulator of caspase activation. In response to DNA damage, sympathetic neurons overcome XIAP and develop sensitivity to cytochrome c by specifically upregulating Apaf-1. Induction of Apaf-1 was the only step required by etoposide to sensitize p53-deficient neurons to cytochrome c. p53-deficient cells in which Apaf-1 induction had been restored by overexpression underwent apoptosis in response to cytochrome c even in the absence of etoposide treatment (Supplementary Figure S4) . Strict control of caspase activation by XIAP in neurons presumably functions as a safety brake that would prevent apoptosis from occurring in the event of accidental mitochondrial damage resulting in cytochrome c release. However, in situations where death is inevitable, such as during development or after irreparable DNA damage, the efficient removal of this brake is important as it would permit apoptosis thereby avoiding the negative side effects of necrosis. Indeed, both NGF deprivation and DNA damage activate specific pathways that efficiently relieve XIAP at a time that precedes the release of cytochrome c from mitochondria (Figure 1d and 4b) . 11 Thus, apoptosis in XIAP-deficient neurons, although no longer needing the pathway to relieve XIAP, is still dependent on the release of cytochrome c and therefore occurs with a time course that is indistinguishable from wild-type neurons (Supplementary Figure S5) . 11 Although the major components of the intrinsic pathway of apoptosis are conserved in both developmental (NGF deprivation) and pathological (DNA damage) apoptosis in sympathetic neurons, this study has identified unique differences in the way this pathway is regulated between these two models. Removal of NGF in these neurons selectively targets XIAP for degradation, whereas DNA damage overcomes XIAP by a p53-mediated induction of Apaf-1 (model in Figure 6a ). We note that biochemical and overexpression studies have shown that mature Smac can also directly bind XIAP and inhibit its activity. 32 However, endogenous Smac does not function to relieve XIAP following DNA damage in neurons, as both wild-type and Smacdeficient sympathetic neurons undergo apoptosis with a similar time course following etoposide treatment (Figure 6b) . Thus, neurons appear to have evolved multiple Smac-independent pathways that are sufficient to relieve XIAP and permit cytochrome c-dependent apoptosis. Similar pathways may also be engaged in other postmitotic cells such as cardiomyocytes where relieving XIAP is necessary for apoptosis.
Apaf-1 has been shown to be induced in a p53-dependent manner in response to camptothecin in cortical neurons. 24 However, whether the p53-mediated induction of Apaf-1 was necessary for neuronal apoptosis was not specifically examined. Indeed, p53 deficiency blocks apoptosis in response to DNA damage in many cells including neurons. 16, 33 However, studies investigating the mechanism of p53 action have primarily focused on events preceding cytochrome c release. For example, proapoptotic members of the Bcl-2 family proteins such as Bax, Noxa and Puma are transcriptional targets of p53, and their upregulation can promote cytochrome c release in cells. 14, 20 In addition, recent studies show that p53 can directly induce cytochrome c release by localizing to mitochondria. 21, 22, 29, 30 Our results now uncover an essential postmitochondrial function of p53 in apoptosis. Although p53-mediated induction of Apaf-1 is likely to occur in multiple cell types exposed to DNA damage, we expect that it is required only in cells where the inactivation of XIAP is necessary for cytochrome c-mediated apoptosis, such as neurons and cardiomyocytes. In addition, as overexpression of XIAP is seen in many cancers, 34 our results predict that p53 activity could also overcome XIAP's inhibition of caspases by elevating Apaf-1 in such cancers. Several studies show that p53 is induced following a variety of neuronal injury paradigms such ischemia, hypoxia and excitotoxicity 16, 18 as well as in neurodegenerative diseases such as amyotrophic lateral sclerosis. 35 Importantly, mice deficient in p53 are protected against glutamate or kainic acidexcitotoxic injury 36 and ischemic brain damage. 37 Our results predict that in these models, p53 deficiency would inhibit neuronal apoptosis not only by blocking cytochrome c release but also by preventing the ability of these neurons to overcome XIAP, thus regulating apoptosis at both pre-and postmitochondrial steps.
Having multiple checkpoints in the regulation of apoptosis, and being able to precisely regulate these checkpoints, is critical for balancing a neuron's long-term survival with the need to undergo apoptosis when physiologically appropriate. An understanding of how these checkpoints are differentially regulated between mitotic and postmitotic cells is clinically significant as it allows for the development of therapeutics that could inhibit or activate apoptosis in selective cells in the context of neurodegenerative diseases or cancers.
Materials and Methods
Reagents. All reagents were purchased from Sigma (St Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA) unless otherwise stated. Collagenase and trypsin were purchased from Worthington Biochemical Corporation (Freehold, NJ, USA), and cycloheximide was purchased from Tocris Cookson (Ellisville, MO, USA). The pan-caspase inhibitor zVAD-fmk was purchased from Enzyme Systems Products. The Apaf-1 cDNA was a gift from Dr. Gabriel Nunez (University of Michigan, Ann Arbor, MI, USA). Recombinant Smac protein was purified from bacteria as described previously.
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Sympathetic neuronal cultures. Primary sympathetic neurons were dissected from the superior cervical ganglia of postnatal day 0-1 mice (P0-P1) and maintained in culture as described previously. 38 Cells were plated on collagencoated dishes at a density of 60 000 cells per well for Western or RT-PCR analysis, or 10 000 cells per well for microinjection, survival counts or immunofluorescence experiments. Sympathetic neurons were grown for 4-5 days in NGF-containing media before treating them with experimental conditions. For treatments, etoposide was used at a concentration of 20 mM. For NGF deprivation, cultures were rinsed three times with medium lacking NGF, followed by the addition of goat anti-NGF neutralizing antibody to this media. Other conditions required the addition of 1 mg/ml cycloheximide or 50 mM zVAD-fmk.
ICR outbreed mice (Harlan Sprague Dawley) were used for all experiments except those involving Bax-, Apaf-1-and p53-deficient sympathetic neurons. The genetic background of Bax-, Apaf-1-, p53-and Smac-deficient mice is C57BL/6; wild-type littermates were used as controls in these experiments. Apaf-1-deficient mice were generated by Joachim Herz (UT Southwestern) 39 and were kindly provided by the laboratory of Dr. Susan Ackerman (Jackson Laboratories). Heterozygous p53 mice were obtained from Jackson Laboratories (Maine). Smacdeficient mice were provided by the laboratory of Dr. Tak Mak (University of Toronto). Our methods for breeding and genotyping Bax-deficient mice have been described previously. 40 The specific primers used to genotype Apaf-1-, p53-or Smac-deficient mice are listed in the online Supplementary materials and methods section.
Immunofluorescence analysis. The status of cytochrome c (whether intact in the mitochondria or released) was examined by immunofluorescence. Briefly, sympathetic neurons were cultured for 4 days following which they were left untreated or treated with 20 mM of etoposide for various time points. Neurons were then fixed in 4% paraformaldehyde and incubated overnight in anti-cytochrome c primary antibody (556432, BD Biosciences) followed by a 2 h incubation with antimouse Cy3 secondary antibody (Jackson Labs). Nuclei were stained with Hoechst 33258 (Molecular Probes).
Microinjection and quantitation of cell survival. Our method of microinjecting sympathetic neurons with cytochrome c has been described previously. 5 Immediately after injections, the number of viable cells injected was determined by counting rhodamine-positive cells that had intact phase-bright bodies. This method of assessing neuronal survival correlates well with other cellsurvival assays such as Trypan blue exclusion and staining with calcein AM. 11 At various times after injections, the number of viable injected neurons remaining was determined by using the same counting criteria and expressed as a percentage of the original number of microinjected cells.
In experiments involving microinjection of DNAs, the Apaf-1-expressing plasmid or empty vector was injected into neurons. The nucleus was injected with 200 ng/ml of the plasmid DNA along with 50 ng/ml of EGFP-expressing DNA (Clonetech laboratories Inc.) in microinjection buffer. After 24 h to allow for expression, GFPexpressing cells were identified by fluorescence microscopy and re-injected with cytochrome c. The survival of these double-injected cells was assessed by morphological criteria.
Western blot analysis. Western analysis was performed as described previously. 11 The following antibodies were used; anti-Apaf-1 (13F11; Alexis Biochemicals), anti-XIAP (AF822; R&D Systems), anti-LDH (Rockland), anti-alphatubulin (Sigma). Anti-mouse/rabbit HRP-conjugated secondary antibodies were purchased from Pierce Chemical Co. For quantitation, Western blots were developed with ECL-plus reagents (Amersham Biosciences) and analyzed on a Typhoon fluorescent imager (Amersham Biosciences) using Image Quant software (Amersham Biosciences). 
